Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 3Stomach Neoplasms 1Prostatic Neoplasms 1Neoplasms 1Liver Neoplasms 1Hepatitis 1Glioblastoma 1Gastrointestinal Neoplasms 1Fibrosis 1Carcinoma, Squamous Cell 1

Interventions

Oxaliplatin 53Cisplatin 52Fluorouracil 50Capecitabine 48pembrolizumab 39Leucovorin 31Docetaxel 26Trastuzumab 23Paclitaxel 20Irinotecan 20Ramucirumab 13Bevacizumab 12Cetuximab 9Radiotherapy 8Surgical Procedures, Operative 7S 1 (combination) 7Nivolumab 7Epirubicin 7Carboplatin 6olaparib 5Platinum 5Everolimus 5Sunitinib 4Mitomycin 4trastuzumab deruxtecan 3lenvatinib 3epacadostat 3bemarituzumab 3apatinib 3Saline Solution 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Stomach Neoplasms × bavituximab × Clear all
NCT04099641 2023-02-08

An Open Label Study of Bavituximab and Pembrolizumab in Advanced Gastric and GEJ Cancer Patients

OncXerna Theraputics, Inc.

Phase 2 Completed
80 enrolled 14 charts
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡